Michael Cho has over 30 years of experience in business management, startup entrepreneurship, legal & business advisory services, business development, and international business. MIchael is a patent attorney and a member of the state bars in California and Washington. Michael co-founded Kinea Bio in 2020 and served on the board of directors until January 2023. From 2015 to 2023, Michael served as CEO of Curi Bio, a Seattle-based biotech company developing a human cell-based drug discovery and screening platform. During his tenure at Curi Bio, Michael led the development and organic growth of an early-stage startup to a globally-recognized, cutting-edge biotechnology company with significant commercial revenues. Under Michael's leadership, Curi Bio pioneered the development and commercialization of human 3D cell/tissue models and novel analytical tools for applications in drug discovery and preclinical studies, which have been successfully adopted by global pharmaceutical companies seeking human data-based, next-generation functional assays targeting cardiac, muscular and neuromuscular diseases. Michael also led Curi Bio's acquisitions of an AI/ML-based cellular imaging solutions and an advanced cellular optical mapping technology, consummated strategic deals for joint ventures and partnerships with Korean biotech companies, and managed non-dilutive R&D funding efforts which resulted in SBIR grant awards totaling over $10M. Over the years of his executive leadership, Curi Bio raised over $20M in equity and research grant funding, built an IP portfolio of over 20 patents and patent applications, and successfully introduced more than five new products for global distribution all of which have become an essential tool in drug discovery and development programs. In September 2023, Michael returned to Kinea Bio to take on new roles as CFO, Chief Strategy Officer and General Counsel.